T and Leukemic B Cells Aggregate
Showing 1 - 25 of >10,000
Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia Trial in Miami (STING-Dependent Activators (STAVs) Loaded
Not yet recruiting
- Refractory Leukemia
- +4 more
- STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
- Dendritic Cell Vaccine
-
Miami, FloridaUniversity of Miami
Jun 1, 2022
Chronic Lymphocytic Leukemia Trial in Madison ([U-13C]glucose, [13C5]glutamine)
Recruiting
- Chronic Lymphocytic Leukemia
- [U-13C]glucose
- [13C5]glutamine
-
Madison, WisconsinUniversity of Wisconsin
Jun 15, 2022
B Cell Leukemia Trial in Seattle (Autologous CD19 CAR+ EGFTt + T cells)
Active, not recruiting
- B Cell Leukemia
- Autologous CD19 CAR+ EGFTt + T cells
-
Seattle, WashingtonSeattle Children's Hospital
Feb 15, 2022
B-cell Non-Hodgkin's Lymphoma Trial in Shanghai (Human CD19Targeted T Cells Injection)
Recruiting
- B-cell Non-Hodgkin's Lymphoma
- Human CD19Targeted T Cells Injection
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Jun 29, 2022
B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)
Recruiting
- B-cell Non Hodgkin Lymphoma
- regimen with BTK inhibitor +Anti-CD19 CAR T cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- UCAR-T Cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 17, 2023
Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)
Active, not recruiting
- Leukemia
- Acute Lymphoblastic Leukemia
- gene-modified T cells targeted
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 1, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/79b T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 28, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous
Not yet recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-CD19-CAR CMV-specific T-lymphocytes
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 28, 2022
B-cell Lymphoma Trial in Xuzhou (ASCT+CAR-T Cell Infusion)
Recruiting
- B-cell Lymphoma
- ASCT+CAR-T Cell Infusion
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 9, 2023
B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma Trial (Autologous Humanized CD19-Directed Chimeric
Not yet recruiting
- B Cell Acute Lymphoblastic Leukemia (B-ALL)
- B Lineage Lymphoblastic Lymphoma
- Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
- (no location specified)
Jul 27, 2022
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day
Recruiting
- Non Hodgkin Lymphoma (NHL)
- +6 more
- 8/12-Day Production of Car-T Cells
- +2 more
-
Milwaukee, WisconsinMedical College of Wisconsin and Froedtert Hospital
Jul 1, 2022
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- U-CAR-T Cells (LstCAR019)
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg
Recruiting
- B-cell Non Hodgkin Lymphoma
- B-cell Chronic Lymphocytic Leukemia
- Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
- +3 more
-
Milwaukee, WisconsinMedical College of Wisconsin and Froedtert Hospital
Jul 1, 2022
19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)
Recruiting
- 19 and 22+ B Cell Hematologic Tumors
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
-
Wuhan, Hubei, ChinaTongji Hospital
May 19, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/70 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 28, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/22 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 21, 2022
Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)
Recruiting
- Non-Hodgkin Lymphoma
- CD19x22 CAR T Cells
-
Aurora, ColoradoUniversity of Colorado Hospital
Feb 3, 2022
Leukemia Trial in Shenyang (IM19 CAR-T cells)
Recruiting
- Leukemia
- IM19 CAR-T cells
-
Shenyang, Liaoning, ChinaFirst Hospital of China Medical University
Jul 27, 2022
Acute Myeloid Leukemia Trial in Besançon (Sample collection)
Recruiting
- Acute Myeloid Leukemia
- Sample collection
-
Besançon, FranceCHU Besançon
Jan 29, 2021
Leukemia, Lymphoma, Lymphoma, B-Cell Trial in New York (CAR T-Cell Infusion)
Withdrawn
- Leukemia
- +2 more
- CAR T-Cell Infusion
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 4, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jun 30, 2022
Non-hodgkin Lymphoma,B Cell Trial in Shenzhen (Allogeneic CD19 CR-T cell)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Allogeneic CD19 CR-T cell
-
Shenzhen, Guangdong, ChinaLi Yu
Nov 22, 2021